NDAORALTABLETPriority Review
Approved
Jul 2018
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 11h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KRINTAFEL (tafenoquine succinate) is an oral small-molecule antimalarial approved by the FDA in July 2018 for the prevention of malaria relapse in patients with Plasmodium vivax or P. ovale infection. It is a prodrug that generates active metabolites targeting hypnozoites in the liver. The drug represents GSK's contribution to malaria elimination efforts, particularly in endemic regions.
$0.003BPart D
PeakProduct is at peak lifecycle stage with modest Part D adoption (26 claims in 2023), suggesting a niche but established market position with stable team structure.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
KRINTAFEL careers center on specialty/tropical disease commercialization in a niche, mission-driven market. Professionals on this product develop expertise in global health policy, endemic-region market dynamics, and regulatory navigation for neglected tropical diseases—skills that differentiate within pharma and offer meaningful impact in underserved populations.
Brand Manager
Worked on KRINTAFEL at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.